#United States #Carlsbad #ImpediMed #SOZO® #BCRL

ImpediMed Earns Frost & Sullivan's 2025 Technology Innovation Leadership Award

Carlsbad, California - January 15, 2025 - ImpediMed, recognized as a forerunner in medical technologies, has been awarded the Frost & Sullivan 2025 North American Technology Innovation Leadership Award in the Point-of-Care Bioimpedance Spectroscopy sector. This accolade acknowledges the firm’s commitment to enhancing long-term patient results through its innovative SOZO® Digital Health Platform, a non-invasive bioimpedance spectroscopy (BIS) technology specifically targeting unmet healthcare challenges in fluid and body composition monitoring. A key focus of SOZO is its application in detecting breast cancer-related lymphedema (BCRL).

Being a pioneer in lymphedema detection, ImpediMed stands out as it provides the only FDA-cleared BIS technology specifically for assessing BCRL, backed by extensive clinical trials and established practice guidelines. As noted by Isai Pratha Karthik, Ph.D., a Senior Research Analyst at Frost & Sullivan, "ImpediMed's bioimpedance spectroscopy solution accurately distinguishes fluid types, providing an L-Dex® score to recognize early changes for timely clinical interventions in breast cancer-related lymphedema. This includes assessing body composition for muscle and fat loss and managing heart failure with its HF-Dex feature."

Lymphedema, a common side effect of cancer treatment, presents substantial obstacles in healthcare, with studies revealing that about 58% of cancer patients, especially those diagnosed with breast cancer, melanoma, or pelvic cancers, are vulnerable to developing limb lymphedema. For breast cancer patients, this risk heightens based on the treatment received. The innovative BIS technology is transforming breast cancer survival rates, delivering a swift, non-invasive, and highly accurate method for fluid change detection within the body. By transmitting a low-level electrical current through bodily tissues to measure resistance, BIS can pinpoint subclinical lymphedema even before any visible symptoms emerge.

A landmark study, the PREVENT trial, involving over 1,200 patients from healthcare facilities in the U.S. and Australia, showcased the effectiveness of ImpediMed's BIS technology in preventing chronic lymphedema among breast cancer patients. Remarkably, the trial indicated that early detection via BIS technology prevented the progression of chronic lymphedema in 92% of cases, suggesting that SOZO could serve as a standard preventive screening tool across oncology clinics worldwide.

Dr. Parmjot Bains, MD, Managing Director and CEO of ImpediMed, commented, "Through our SOZO Digital Health Platform, we are revolutionizing the assessment and management of fluid and body composition, ultimately enhancing patient outcomes. This award not only reaffirms our focus on improving the lives of patients but also solidifies our leadership status in the industry and inspires us to continue advancing fluid and tissue analysis."

ImpediMed's platform is widely regarded for its effectiveness in accurately screening for lymphedema, with U.S. health insurers providing coverage for over 257 million individuals.

Additionally, the company recently announced that the National Accreditation Program for Breast Centers (NABPC), part of the American College of Surgeons, has revised its 2024 accreditation standards to incorporate lymphedema prevention programs using bioimpedance spectroscopy (BIS) as evidence-based guidelines for early lymphedema detection.

About SOZO Digital Health Platform

SOZO represents the world's most sophisticated, non-invasive bioimpedance spectroscopy device, delivering precise evaluations of fluid status and tissue composition in under thirty seconds. Utilizing ImpediMed’s BIS technology, SOZO records 256 unique data points across a diverse range of frequencies from 3 kHz to 1000 kHz. Results are instantly available online, facilitating seamless data access and sharing within healthcare systems. This FDA-cleared, CE-marked, and ARTG-listed digital health platform assists in early detection of secondary lymphedema and evaluates fluid status in patients experiencing heart or renal failure, serving multiple health monitoring purposes—all via a single device.

About ImpediMed

ImpediMed is a distinguished global medical technology enterprise that develops and manufactures devices using bioimpedance spectroscopy (BIS) for non-invasive assessment and monitoring of fluid status and tissue composition in patients. The organization is dedicated to innovation, particularly addressing the challenges and burdens posed by secondary lymphedema, especially concerning breast cancer-related lymphedema (BCRL). With the SOZO® Digital Health Platform and L-Dex®, ImpediMed uniquely offers FDA-cleared technology employing BIS, setting new benchmarks for early detection and management of BCRL. For further information, visit www.impedimed.com.

About Frost & Sullivan

For over sixty years, Frost & Sullivan has gained global acclaim for its role in assisting investors, business leaders, and governments in navigating economic transitions while identifying disruptive technologies and emerging trends, resulting in a continual flow of growth opportunities for future success.